Cargando…

The Impact of the 2019 European Guideline for Cardiovascular Risk Management: A Cross-Sectional Study in General Practice

The aim of this study was to assess the impact of the 2019 published European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guideline on cardiovascular (CV) risk management compared with its predecessor from 2016 in a cohort in general practice. We performed a cross-sectional re...

Descripción completa

Detalles Bibliográficos
Autores principales: Meier, Rahel, Rachamin, Yael, Rosemann, Thomas, Markun, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408902/
https://www.ncbi.nlm.nih.gov/pubmed/32645925
http://dx.doi.org/10.3390/jcm9072140
_version_ 1783567939807477760
author Meier, Rahel
Rachamin, Yael
Rosemann, Thomas
Markun, Stefan
author_facet Meier, Rahel
Rachamin, Yael
Rosemann, Thomas
Markun, Stefan
author_sort Meier, Rahel
collection PubMed
description The aim of this study was to assess the impact of the 2019 published European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guideline on cardiovascular (CV) risk management compared with its predecessor from 2016 in a cohort in general practice. We performed a cross-sectional retrospective study with data from electronic medical records. The study cohort included 103,351 patients with known CV risk. We assessed changes in CV risk classification and low-density lipoprotein cholesterol (LDL-C) target values, the impact on LDL-C achievement rates, and the current lipid-lowering treatments. Under the 2019 ESC guideline, CV risk categories changed in 27.5% of patients, LDL-C target levels decreased in 71.4% of patients, and LDL-C target achievement rate dropped from 31.1% to 16.5%. Among non-achievers according to the 2019 guideline, 52.2% lacked lipid-lowering drugs entirely, and 41.5% had conventional drugs at a submaximal intensity. Of patients in the high-risk and very high-risk categories, at least 5% failed to achieve the LDL-C target level despite treatment at maximal intensity with conventional lipid-lowering drugs, making them eligible for PCSK-9 inhibitors. In conclusion, the 2019 ESC/EAS guideline lowered LDL-C target values for the majority of patients in general practice and halved LDL-C target achievement rates. There is still a large undeveloped potential to lower CV risk by introducing conventional lipid-lowering drugs, particularly in patients at high or very high CV risk. A substantial proportion of the patients can only achieve their LDL-C targets using PCSK-9 inhibitors, which would currently require an at least 10-fold increase in prescribing of these drugs.
format Online
Article
Text
id pubmed-7408902
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74089022020-08-13 The Impact of the 2019 European Guideline for Cardiovascular Risk Management: A Cross-Sectional Study in General Practice Meier, Rahel Rachamin, Yael Rosemann, Thomas Markun, Stefan J Clin Med Article The aim of this study was to assess the impact of the 2019 published European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guideline on cardiovascular (CV) risk management compared with its predecessor from 2016 in a cohort in general practice. We performed a cross-sectional retrospective study with data from electronic medical records. The study cohort included 103,351 patients with known CV risk. We assessed changes in CV risk classification and low-density lipoprotein cholesterol (LDL-C) target values, the impact on LDL-C achievement rates, and the current lipid-lowering treatments. Under the 2019 ESC guideline, CV risk categories changed in 27.5% of patients, LDL-C target levels decreased in 71.4% of patients, and LDL-C target achievement rate dropped from 31.1% to 16.5%. Among non-achievers according to the 2019 guideline, 52.2% lacked lipid-lowering drugs entirely, and 41.5% had conventional drugs at a submaximal intensity. Of patients in the high-risk and very high-risk categories, at least 5% failed to achieve the LDL-C target level despite treatment at maximal intensity with conventional lipid-lowering drugs, making them eligible for PCSK-9 inhibitors. In conclusion, the 2019 ESC/EAS guideline lowered LDL-C target values for the majority of patients in general practice and halved LDL-C target achievement rates. There is still a large undeveloped potential to lower CV risk by introducing conventional lipid-lowering drugs, particularly in patients at high or very high CV risk. A substantial proportion of the patients can only achieve their LDL-C targets using PCSK-9 inhibitors, which would currently require an at least 10-fold increase in prescribing of these drugs. MDPI 2020-07-07 /pmc/articles/PMC7408902/ /pubmed/32645925 http://dx.doi.org/10.3390/jcm9072140 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Meier, Rahel
Rachamin, Yael
Rosemann, Thomas
Markun, Stefan
The Impact of the 2019 European Guideline for Cardiovascular Risk Management: A Cross-Sectional Study in General Practice
title The Impact of the 2019 European Guideline for Cardiovascular Risk Management: A Cross-Sectional Study in General Practice
title_full The Impact of the 2019 European Guideline for Cardiovascular Risk Management: A Cross-Sectional Study in General Practice
title_fullStr The Impact of the 2019 European Guideline for Cardiovascular Risk Management: A Cross-Sectional Study in General Practice
title_full_unstemmed The Impact of the 2019 European Guideline for Cardiovascular Risk Management: A Cross-Sectional Study in General Practice
title_short The Impact of the 2019 European Guideline for Cardiovascular Risk Management: A Cross-Sectional Study in General Practice
title_sort impact of the 2019 european guideline for cardiovascular risk management: a cross-sectional study in general practice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408902/
https://www.ncbi.nlm.nih.gov/pubmed/32645925
http://dx.doi.org/10.3390/jcm9072140
work_keys_str_mv AT meierrahel theimpactofthe2019europeanguidelineforcardiovascularriskmanagementacrosssectionalstudyingeneralpractice
AT rachaminyael theimpactofthe2019europeanguidelineforcardiovascularriskmanagementacrosssectionalstudyingeneralpractice
AT rosemannthomas theimpactofthe2019europeanguidelineforcardiovascularriskmanagementacrosssectionalstudyingeneralpractice
AT markunstefan theimpactofthe2019europeanguidelineforcardiovascularriskmanagementacrosssectionalstudyingeneralpractice
AT meierrahel impactofthe2019europeanguidelineforcardiovascularriskmanagementacrosssectionalstudyingeneralpractice
AT rachaminyael impactofthe2019europeanguidelineforcardiovascularriskmanagementacrosssectionalstudyingeneralpractice
AT rosemannthomas impactofthe2019europeanguidelineforcardiovascularriskmanagementacrosssectionalstudyingeneralpractice
AT markunstefan impactofthe2019europeanguidelineforcardiovascularriskmanagementacrosssectionalstudyingeneralpractice